Search

everythinglearnresearchcommunity

for

Search:↓

Both Th1 and Th2 immune responses are increased in alopecia areata, with Th2 response more strongly linked to how severe the disease is.

Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.

Canine pemphigus foliaceus involves significant immune activity and shares similarities with human pemphigus.

New treatments targeting immune pathways show promise for severe hair loss but need more research for safety and effectiveness.

Targeted cytokine treatments may help with alopecia areata, but more research is needed.

Different parts of the body have unique immune characteristics in their skin.

Apremilast was not effective in treating moderate-to-severe alopecia areata.

Alopecia areata is an autoimmune condition causing hair loss, linked to genetic factors and immune system issues, with no cure yet.

848 genes related to fat and metabolism are less active in people with Central Centrifugal Cicatricial Alopecia.

Current treatments for Alopecia Areata have mixed success, and there's a need for better, more accessible options and support for affected individuals.

Alopecia areata patients show increased inflammation and OX40 activation, suggesting a new treatment target.

Tofacitinib helped most patients with alopecia areata regrow hair and changes in immune cells were linked to the treatment's effectiveness.

The review suggests that other immune cells besides CD8+ T cells may contribute to alopecia areata and that targeting regulatory cell defects could improve treatment.

Hair follicle-derived IL-7 and IL-15 are crucial for maintaining skin-resident memory T cells and could be targeted for treating skin diseases and lymphoma.

Vitamin B5 and coenzyme A may help regulate the immune system and could improve treatments for chronic diseases and cancer.

No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.

Alopecia areata involves immune activation in the scalp, suggesting treatments targeting TH1, TH2, and IL-23 pathways.

Frontal fibrosing alopecia shows increased inflammation and JAK-STAT pathway activity without reduced hair proteins.

Chronic graft-versus-host disease in the skin shows strong Th1 immune response and unique barrier issues.

Dupilumab treatment reduces Th2-related markers and helps hair growth in alopecia areata, showing Th2's role in the condition.

Corticosteroid treatment reduces inflammation and alters hair keratins in alopecia areata.

Acne patients' skin, both with and without lesions, shows a strong immune response and higher antimicrobial activity.

Frontal fibrosing alopecia is linked to increased immune system activity and reduced stem cells, suggesting early treatment targeting this pathway might prevent hair follicle damage.

Anti-IL-12/IL-23 antibody therapy effectively treats psoriasiform skin lesions in IBD patients.

People with alopecia areata may have a higher risk of blood clots.

Alopecia areata severity and treatment response are linked to specific cytokine levels.

Four genes are potential markers for hair loss condition alopecia areata, linked to a specific type of cell death.

2011 dermatological research found new skin aging markers, hair loss causes, skin defense mechanisms, and potential for new treatments.

Blocking IL-12/IL-23p40 helped reverse severe hair loss in patients.

Wnt/beta-catenin signaling in the skin helps fat cell development during hair growth and repair.